{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"282"}],"units":"Participants"}],"title":"Baseline evaluable participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"267"}],"units":"Participants"}],"title":"Post-baseline evaluable participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"282"}],"units":"Participants"}],"groups":[{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"The baseline ADA-evaluable population included participants who had a baseline ADA result and had received at least one dose of atezolizumab. The post-baseline ADA evaluable population included participants who had at least one post-baseline ADA result and had received at least one dose of atezolizumab.","reportingStatus":"POSTED","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)","title":"Percentage of Participants With Anti-therapeutic Antibodies (ATAs)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}